Visions for the future in osteoporosis research

G. R. Mundy

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


An ideal therapeutic agent for osteoporosis - one that both inhibits osteoclastic bone resorption and stimulates new bone formation - is not currently available. Currently available resorption inhibitors (estrogen, bisphosphonates, and calcitonin) prevent further bone loss and stabilize bone mass. However, they have a negligible to very modest effect on bone formation over prolonged periods, and do not cause prolonged increases in bone mass. A universally acceptable bone formation stimulator is not currently available. Future research is likely to focus on the use of peptide growth factors to stimulate appositional bone growth, or on the use of low molecular weight compounds that may selectively stimulate bone cells to produce these factors in the local bone remodeling microenvironment.

Original languageEnglish (US)
Pages (from-to)29-34
Number of pages6
JournalOsteoporosis International
Issue number2 Supplement
StatePublished - Mar 1993


  • Bone formation
  • Bone remodeling
  • Bone resorption
  • Fluoride
  • Growth factors
  • Osteoclasts

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Visions for the future in osteoporosis research'. Together they form a unique fingerprint.

Cite this